Table 1 Patient characteristics and results of sequencing and D-HPLC

From: Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

Patient # Sex Age (years) Disease Disease phase at initiating imatinib Duration of imatinib treatment prior to analysis (weeks) Best response to imatinib Disease state at the time of analysis Sequence Leipzig nucleotide exchange Sequence Leipzig amino acid exchange Sequence Portland D-HPLC-5′ D-HPLC-3′ BCR-ABL/ABL ratio
1 m 64 CML M-BC 17 CHR Hematological relapse in M-BC G1127A E255K E255K MUT WT 114
2 m 48 CML CP2 0 CHR Initial WT WT ND WT WT 87
3 m 65 CML CP1 39 CCR Cytogenetic relapse T1121C Y253H Y253H MUT WT 79
4 f 62 CML AP 8 PHR Hematological relapse in AP C1308T T315I T315I MUT WT 17
5 f 53 CML M-BC 4 NR Hematological relapse in M-BC C1308T T315I T315I MUT WT 66
6 m 46 CML AP 10 PHR Hematological relapse in AP WT WT WT WT WT 117
7 f 62 CML AP 26 PHR PHR A1128T E255V E255V MUT WT 68
8 m 55 CML AP 0 NR Initial WT WT ND WT WT 113
9 m 52 CML AP 37 CHR Hematological relapse in AP T1416C M351T M351T WT MUT 70
10 m 60 CML L-BC 20 MCR Hematological relapse in AP A1315C F317L F317L MUT WT Failed
11 f 47 CML AP 29 CHR Hematological relapse in AP T1416C M351T M351T WT MUT 70
12 f 68 CML CP2 10 CP Stable disease WT WT ND WT WT 78
13 f 69 CML AP 33 PHR Hematological relapse in AP A1551G H396R H396R WT MUT 72
14 f 69 CML L-BC 11 PHR Hematological relapse in M-BC WT WT ND WT WT Failed
15 f 40 CML M-BC 23 CHR Hematological relapse in M-BC WT WT ND WT WT 42
16 f 24 CML M-BC 92 CHR Hematological relapse in M-BC T1121C Y253H Y253H MUT WT 67
17 f 60 CML M-BC 8 NR Initial WT WT (T315I)a MUT WT 23
18 f 59 CML M-BC 29 PHR Hematological relapse in M-BC T1439A F359I F359I + S417Yb WT MUT Failed
19c f 59 ALL CR2 52 Started in CR Hematological relapse T1439G F359V F359V WT MUT ND
20c f 59 ALL CR2 52 Started in CR Hematological relapse T1439G F359V F359V WT MUT ND
21 m 53 CML M-BC 3 NR Initial WT WT ND WT WT 13
22 m 65 ALL 2. relapse 8 CHR Hematological relapse T1121C Y253H Y253H MUT WT Failed
23 m 52 CML CP1 56 CHR Hematological relapse in CP WT WT ND WT WT Failed
24 m 58 CML M-BC 17 CHR Hematological relapse in CP WT WT ND WT WT 79
25 m 46 CML AP 17 NR Hematological relapse in AP WT WT ND WT WT Failed
26 m 73 CML M-BC 63 CCR Hematological relapse in M-BC T1416C M351T M351T MUT WT 127
27 m 40 CML CP1 17 PHR Hematological relapse in CP A1122T Y253F Y253F MUT WT 42
28 f 67 CML CP1 15 CHR Hematological relapse in CP WT WT ND WT WT 63
29 f 56 CML M-BC 5 NR Initial WT WT ND WT WT 134
30 m 57 CML CP1 0 NN Initial WT WT ND WT WT 54
  1. AP – accelerated phase; CHR – complete hematological remission; CP – chronic phase; L-BC – lymphoid blast crisis; M-BC – myeloid blast crisis; MUT – mutant; UNK – not known; NR – no response; PHR – partial hematological remission; WT – wild type.
  2. aIn patient #17, the mutation was detected only after cloning of PCR products and sequencing of individual clones.
  3. bAmino acid 417 was not included in the PCR product sequenced in Leipzig.
  4. c#19 (peripheral blood) and 20 (bone marrow) are from the same patient.